#obesity drug

1 story

#cash burn #glp-1/gip #maintenance dosing #phase 3 trial #viking therapeutics #viking therapeutics vktx #vk2735

Viking Therapeutics Data Boosts Hope but Cash Burn Lingers
Viking Therapeutics shows strong VK2735 maintenance data but cash runway remains tight for obesity drug candidate.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m